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Abstract
Introduction: Dexmedetomidine is a selective and potent alpha2-adrenoceptor agonist licensed for use in the
sedation of patients initially ventilated in intensive care units at a maximum dose rate of 0.7 μg/kg/h administered
for up to 24 hours. Higher dose rates and longer infusion periods are sometimes required to achieve sufficient
sedation. There are some previous reports on the use of long-term moderate to high-dose infusions of
dexmedetomidine in patients in intensive care units, but none of these accounts have cited dexmedetomidine
plasma concentrations.
Case presentation: We describe the case of a 42-year-old Caucasian woman with severe hemorrhagic pancreatitis
following laparoscopic cholecystectomy who received dexmedetomidine for 24 consecutive days at a maximum
dose rate of 1.9 μg/kg/h. Samples for the measurement of dexmedetomidine concentrations in her plasma were
drawn at intervals of eight hours. On average, the observed plasma concentrations were well in accordance with
previous knowledge on the pharmacokinetics of dexmedetomidine. There was, however, marked variability in the
concentration of dexmedetomidine in her plasma despite a stable infusion rate.
Conclusion: The pharmacokinetics of dexmedetomidine appears to be highly variable during intensive care.
Introduction
Dexmedetomidine is a selective and potent alpha2-adre-
noceptor agonist licensed for the sedation of patients
initially ventilated in intensive care units (ICU) at a maxi-
m u md o s er a t eo f0 . 7μg/kg/h administered for up to 24
hours. Higher dose rates and longer infusion periods are
sometimes required to achieve sufficient sedation. We
describe the case of a 42-year-old Caucasian woman with
severe hemorrhagic pancreatitis following laparoscopic
cholecystectomy, who received dexmedetomidine for 24
consecutive days at a maximum dose rate of 1.9 μg/kg/h.
Case presentation
A 42-year-old Caucasian Finnish woman was scheduled
for laparoscopic cholecystectomy due to typical symp-
toms and radiological findings of gallstones. She was
obese (89 kg, BMI = 33), even though she had managed
to lose weight by 20 kg six months prior to presenta-
tion. She was using sibutramine and oral contraceptives
as regular medication.
Surgery was uneventful, but on the second postopera-
tive day, the general state of our patient started to dete-
riorate, resulting in anuria and difficulty of breathing,
admission into the intensive care unit (ICU), endotra-
cheal intubation, and mechanical ventilation. Endoscopic
retrograde cholangiopancreatography (ERCP) was
performed upon ICU admission because of suspected
biliary tract leakage. However, no signs of leakage were
observed. Computed tomography (CT) examination
revealed fluid around her liver, while her pancreas could
not be visualized. Her plasma amylase concentration was
elevated, thus confirming the diagnosis of pancreatitis.
Due to decreased renal function, she was commenced
on continuous hemodiafiltration therapy on the third
day and continued until the 10th postoperative day. Pro-
pofol infusion for sedation, supplemented with intrave-
nous oxycodone boluses, was started as part of our
hospital’s standard therapy in order to facilitate
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Propofol sedation was continued until the 36th post-
operative day. Upon the decision of weaning, her attend-
ing physician decided to add dexmedetomidine infusion
into the sedation regimen 17 days after her surgery.
Weaning was not successful, and tracheostomy was per-
formed on the 18th postoperative day. On the 19th post-
operative day, esophagogastroduodenoscopy and
explorative laparotomy were performed because the gen-
eral condition of our patient again started to deteriorate.
Hemorrhagic pancreatitis with severe inflammation of her
abdominal cavity was discovered. This deterioration pre-
v e n t e df u r t h e rw e a n i n g .O u ra i mw a st os t o pp r o p o f o l
infusion after starting her on dexmedetomidine, but in
order to achieve the desired level of sedation (light to
moderate, Sedation-Agitation Scale (SAS) levels 3 to
4 [1]), propofol infusion had to be continued despite the
already high dose of dexmedetomidine she was receiving.
Our patient later required yet another laparotomy
because of elevated abdominal pressure. This surgery did
not reveal any additional findings, but this time her
abdominal wall had to be left open, and sedation had to be
continued. Vacuum-assisted closure therapy was estab-
lished on the 22nd and continued until the 34th post-
operative day. Weaning was started again on the 36th
postoperative day. Clonidine infusion was started on the
40th postoperative day, while the dexmedetomidine infu-
sion was discontinued on the following day, on the 24th
day of its administration.
Our patient’s abdominal wall was finally closed on the
47th day, and the clonidine infusion was stopped on the
51st postoperative day. The tracheostomy cannula was
removed on the 54th day and she was admitted to a sur-
gical ward on the 55th postoperative day for further
recovery.
During dexmedetomidine sedation, her plasma albumin
level was low (8.4 g/L to 11.6 g/L) and her creatinine level
was slightly elevated (23 μmol/L to 126 μmol/L). Mean-
while, her bilirubin level and international normalized
ratio (INR) were both normal at 5 μmol/L to 16 μmol/L
and 1.1 to 1.4, respectively.
At 14 months later, her recovery is still incomplete.
Already in the ICU she complained that her vision is
impaired. According to the consulting ophthalmologist,
this symptom is likely due to ischemic optic neuropathy.
At present she can only see movement and light with
her right eye. The vision of her left eye is also severely
impaired, but she is able to read using special equip-
ment for the visually impaired. Additionally, her every-
day life is harmed by numbness and weakness of her
extremities, which is caused by critical illness polyneuro-
pathy. Despite these impairments, her aim is to return
to work.
Samples for the measurement of dexmedetomidine
concentrations in her plasma were drawn at 8-hour
intervals as directed by the plan of the pharmacokinetic
study she was recruited in. The concentrations
were determined using reversed-phase high-performance
Figure 1 Dexmedetomidine infusion rate and plasma concentrations. Propofol infusion rate, dexmedetomidine infusion rate and plasma
dexmedetomidine concentration during the 24-day high-dose infusion in a critically ill intensive care patient (Dex, dexmedetomidine; Conc,
concentration).
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metric detection (PE Sciex API4000 instrument; PE
Sciex, Foster City, California, US) as described pre-
viously [2].
The rates of the dexmedetomidine and propofol infu-
sions, as well her plasma concentration results of dex-
medetomidine, are presented in Figure 1. In calculating
the dexmedetomidine dose, we used her preoperative
weight of 89 kg.
Because the dose rate of dexmedetomidine remained
constant for relatively long periods of time during three
separate intervals, we calculated the plasma clearance of
dexmedetomidine during these intervals by dividing the
infusion rate by the plasma concentration. The calculated
clearance was 55 L/h, 92 L/h and 87 L/h during the 2nd
to 6th, 14th to 20th and 21st to 23rd day of the dexmede-
tomidine infusion, respectively. A list of drugs adminis-
tered during her ICU stay is presented in Table 1.
Table 1 Drugs administered during our patient’s stay at the intensive care unit.
Start (day) Stop (day) Dosage
Regularly administered drugs
Calcium glubionate 3 21 90 mg × 2 - 6 iv
Enoxaparin 3 9 20 mg to 40 mg when needed for CVVHDF
10 54 40 mg × 1 sc
Sodium polystyrene sulfonate 3 3 30 g × 1 pr
Pantoprazol 3 54 40 mg × 1 iv
Imipenem 3 39 250 mg to 1000 mg × 3 iv
Ondansetron 3 3 4 mg × 2 iv
Lactulose 6 9 20 g × 3 po
Vancomycin 8 54 1000 mg × 2 iv (based on the serum concentration)
Metronidazole 11 19 400 mg × 3 po
19 26 500 mg × 3 iv
Fluconazole 12 51 400 mg × 1 iv
Hydrocortisone 13 15 100 mg × 3 iv
Ciprofloxacin 18 39 400 mg × 2 iv
Tigecycline 39 54 50 mg × 2 iv
Infusions
Short-acting insulin 3 54 0.5 - 20 IU/h
Furosemide 3 3 1000 mg/day
6 36 70 - 1000 mg/day
Norepinephrine 3 31 Maximum dose 0.19 μg/kg/min
Propofol 3 36 See Figure 1.
Dexmedetomidine 17 41 See Figure 1.
Metoprolol 38 40 1 - 2 mg/h
Clonidine 40 51 Maximum dose 2.2 μg/kg/h
Drugs administered when needed
Propofol 3 37 20 - 50 mg iv
Diazepam 3 3 2.5 mg iv
Lorazepam 26 41 1 - 4 mg iv
Haloperidol 36 55 2.5 - 5 mg iv
Fentanyl 3 31 Occasional doses of 50 - 200 μgi v
Oxycodone 3 53 5 - 10 mg iv
Acetaminophen 11 21 Occasional doses of 1000 mg po/iv
Furosemide 3 52 5 - 10 mg iv
Ephedrin 3 3 5 mg iv
Rocuronium 3 32 Occasional doses of 10 - 50 mg iv
Indapamide 15 15 2.5 mg × 1
Metoprolol 26 42 Occasional doses of 2.5 - 5 mg iv
Days refer to postoperative days. IV, intravenous; po, per os; pr, per rectum; IU, international units; CVVHDF, continuous veno-venous hemodiafiltration.
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There are some previous reports on the use of long-
term moderate to high dose infusions of dexmedetomi-
dine in ICU patients [3], but none of these accounts
have reported dexmedetomidine plasma concentrations.
In our patient, the infusion rates were higher than
recommended, and her dexmedetomidine plasma levels
were measured over a 3-week infusion period. On the
average, our patient’s observed plasma concentrations
were well in accordance with previous knowledge on the
pharmacokinetics of dexmedetomidine in humans [4].
However, the concentration of our patient’s dexmedeto-
midine greatly varied even during unchanged infusion.
The plasma concentration of dexmedetomidine
decreased by one-third (2.9 ng/ml to 1.7 ng/ml) on days
6 to 8 despite a constant rate of infusion. The concen-
tration of any drug at a steady state is dependent only
on its plasma clearance and the rate of infusion.
Accordingly, the calculated clearance of dexmedetomi-
dine was increased by 60%. The reason for the increased
clearance can only be speculated.
Dexmedetomidine is almost completely eliminated by
metabolism in the liver. It is mainly N-glucuronidated
by glucuronyl transferases and hydroxylated by several
cytochrome P450 enzymes [5], but none of the drugs
which were administered at the time of the apparent
change in dexmedetomidine clearance are known to
induce the activities of glucuronyl transferases or cyto-
chrome P450 enzymes. It is thus logical to assume that
changes in hemodynamic variables could have affected
the pharmacokinetics of dexmedetomidine.
Although there is no direct information on the extrac-
tion ratio of dexmedetomidine in humans, the reported
values of dexmedetomidine clearance (40 L/h to 70 L/h
in adults) [4] suggest that the extraction ratio of dexme-
detomidine is rather high, and its clearance may thus be
dependent on liver perfusion. This hypothesis is sup-
ported by data from Ebert et al. [6] and Snapir et al.[ 2 ]
who observed that high-dose target controlled infusions
of dexmedetomidine produced higher plasma concentra-
tions than expected, probably due to decreased cardiac
output caused by dexmedetomidine itself. Unfortunately,
we have no data from our patient on cardiac output or
intestinal perfusion at the time of major changes in her
dexmedetomidine clearance. Nevertheless, the increase in
apparent dexmedetomidine clearance coincided with the
general improvement of the condition of our patient. For
instance, the dose rate of norepinephrine required to
maintain her hemodynamic function was significantly
reduced on the 5th day of the dexmedetomidine infusion.
Although the dose rate of dexmedetomidine was high,
its sedative effect had to be enhanced with propofol. It
is quite common that several different types of drugs
acting via different mechanisms are combined during
long-term ICU treatment. Our patient was commenced
on clonidine because clonidine was routinely used to
facilitate the termination of long sedation or opioid infu-
sions at the time of the study. However, in the case of
dexmedetomidine, the change to another alpha2-adreno-
ceptor agonist was probably unnecessary.
Our patient developed optic neuropathy probably
because of cerebral ischemia secondary to hypotension,
hypoxia or embolism. Although a toxic mechanism can-
not be excluded, we have no reason to believe that this
complication was due to dexmedetomidine. There is a
plethora of underlying conditions for ischemia during
critical illness and there are no previous reports of toxic
neuropathy following dexmedetomidine infusion.
Conclusion
During our patient’s 24-day high-dose dexmedetomidine
infusion, her observed plasma concentrations were on
the average well in accordance with previous knowledge
on the pharmacokinetics of dexmedetomidine in
humans. There was, however, a marked variability in the
concentration of dexmedetomidine in her plasma
despite a stable infusion rate. We conclude that the
pharmacokinetics of dexmedetomidine appears to be
highly variable during intensive care. However, the phar-
macokinetics of dexmedetomidine appears to be linear
even at high-dose and long-lasting administration. We
observed no unexpected accumulation of dexmedetomi-
dine during the infusion.
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